pancuronium
Trade name: pavulon
Approved
Oct 24, 1972
Pancuronium (trademarked as Pavulon) is an aminosteroid muscle relaxant with various medical uses. Pancuronium is a typical non-depolarizing curare-mimetic muscle relaxant. It competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction by blocking the binding of acetylcholine. It has slight vagolytic activity, causing an increase in heart rate, but no ganglioplegic (i.e., blocking ganglions) activity. It is a very potent muscle relaxant drug, with an ED95 of only 60 µg/kg body weight. The onset of action is relatively slow compared to other similar drugs, in part due to its low dose - an intubating dose takes 3–6 minutes for full effect. Clinical effects (muscle activity lower than 25% of physiological) last for about 100 minutes. The time needed for full (over 90% muscle activity) recovery after single administration is about 120–180 minutes in healthy adults. Pancuronium is used with general anesthesia in surgery for muscle relaxation and as an aid to intubation or ventilation. It does not have sedative or analgesic effects. Side-effects include moderately raised heart rate and thereby arterial pressure and cardiac output, excessive salivation, apnea and respiratory depression, rashes, flushing, and sweating. The muscular relaxation can be dangerous for the seriously ill and it can accumulate leading to extended weakness. Pancuronium is not preferable to long-term use in ICU-ventilated patients. Pancuronium is also used as one component of a lethal injection in the administration of the death penalty in some parts of the United States. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 7 marketing orgs
Timeline
1980s
- Mar 23, 1988
Elkins Sinn — Marketing Organization
- Jan 19, 1989
Hospira — Marketing Organization
1990s
- Jul 31, 1990
Teva — Marketing Organization
- Jul 31, 1990
Dr. Reddy's Laboratories — Marketing Organization
Indications
Approved for
Mechanism of action
Muscle-type nicotinic acetylcholine receptor antagonist
non-depolarizing
Approval history
- approvedPriority reviewOct 24, 1972
Chemistry & pharmacology
SMILES
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1- Mol. weight
- 572.88 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL185073 ↗
- WikipediaPancuronium bromide ↗
- NCATSJ76UF062FS ↗
- ChEMBLCHEMBL1200757 ↗
Also known as
- bromure de pancuronium
- bromure de pancuronium
- bromurex
- bromuro de pancuronio
- bromuro de pancuronio
- mioblock
- mioblock
- org na 97
- org na 97
- org-na 97
- org-na 97
- pancuronium
- pancuronium
- pancuronium
- pancuronium
- pancuronium
- pancuronium
- pancuronium bromide
- pancuronium bromide
- pancuronium bromide
- pancuronium bromide
- pancuronium bromide
- pancuronium bromide
- pancuronium bromide
- pancuronium dibromide
- pavulon
- pavulon
- pavulon
Organizations
Marketing (7)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Athenex, Inc. | For profit | MKTG | — |
| Dr. Reddy's Laboratories | For profit | MKTG | Jul 31, 1990 |
| Elkins Sinn | For profit | MKTG | Mar 23, 1988 |
| Hospira | For profit | MKTG | Jan 19, 1989 |
| Organon | For profit | NDA | Oct 24, 1972 |
| Teligent Pharmaceuticals | For profit | MKTG | — |
| Teva | For profit | MKTG | Jul 31, 1990 |